CorMedixCRMD
Market Cap: 250M
About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
Employees: 82
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
4% more capital invested
Capital invested by funds: $70.4M [Q4 2023] → $73.2M (+$2.82M) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]
10% less funds holding
Funds holding: 100 [Q4 2023] → 90 (-10) [Q1 2024]
20.29% less ownership
Funds ownership: 51.7% [Q4 2023] → 31.41% (-20.29%) [Q1 2024]
32% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 34
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
68% less call options, than puts
Call options by funds: $394K | Put options by funds: $1.24M
Research analyst outlook
8 Wall Street Analysts provided 1 year price forecasts over the past 6 months
8 analyst ratings
Truist Securities Joon Lee | 164%upside $12 | Buy Maintained | 25 Jul 2024 |
Needham Serge Belanger | 120%upside $10 | Buy Reiterated | 19 Jun 2024 |
Needham Serge Belanger | 120%upside $10 | Buy Reiterated | 13 May 2024 |
JMP Securities Jason Butler | 319%upside $19 | Market Outperform Reiterated | 9 Apr 2024 |
Needham Serge Belanger | 120%upside $10 | Buy Reiterated | 9 Apr 2024 |